Skip to Content
Merck
CN
All Photos(1)

Documents

04-290

Sigma-Aldrich

Anti-EGFR (CT) Antibody, clone 13G8

clone 13G8, from mouse

Sign Into View Organizational & Contract Pricing

Synonym(s):
ERBB, mENA, ERBB1
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified antibody

antibody product type

primary antibodies

clone

13G8, monoclonal

species reactivity

mouse, human

manufacturer/tradename

Chemicon®
Upstate®

technique(s)

ELISA: suitable
immunocytochemistry: suitable
western blot: suitable

isotype

IgG1

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... EGFR(1956)
mouse ... Egfr(13649)

Specificity

Recognizes C-terminus domain of EGF receptor (aa1165-1186)

Immunogen

KLH-conjugated synthetic peptide encompassing the surrounding amino acids of the C terminus in human EGFR

Application

Anti-EGFR (C-terminus) Antibody, clone 13G8 detects level of EGFR (C-terminus) & has been published & validated for use in ELISA, IC & WB.
Research Category
Signaling
Research Sub Category
Growth Factors & Receptors

Quality

Routinely evaluated by immunoblot.

Target description

180 kDa

Linkage

Replaces: 04-337; 04-338

Physical form

100 µg of purified mouse monoclonal IgG lyophilized in PBS containing 0.09% sodium azide, PEG, and sucrose
Format: Purified
Subsequent thiophilic adsorption and size exclusion chromatography

Storage and Stability

2 years at -20°C from date of shipment

Analysis Note

Control
Includes EGF treated Hep2G lysate as a positive control

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Francesca Walker et al.
Experimental cell research, 313(3), 511-526 (2006-12-13)
The site of action of growth factors on mammalian cell cycle has been assigned to the boundary between the G1 and S phases. We show here that Epidermal Growth Factor (EGF) is also required for mitosis. BaF/3 cells expressing the
Katsuyuki Hotta et al.
Oncology reports, 17(2), 313-317 (2007-01-05)
Despite its tremendous antitumor effect in a subset of patients with non-small cell lung cancer (NSCLC), the exact mechanism of gefitinib-induced cell death has not been fully determined. In this study, forms of cell death in various NSCLC cell lines
Xiaozhu Zhang et al.
Journal of medical genetics, 44(3), 166-172 (2006-12-13)
Frequent overexpression of epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) makes EGFR a new therapeutic target. Two specific EGFR tyrosine kinase inhibitors, gefitinib (ZD1839, Iressa) and erlotinib (OSI-774, Tarceva), have been developed and approved by the US
David W M Tan et al.
Development (Cambridge, England), 140(7), 1433-1444 (2013-03-14)
Human epidermal stem cells express high levels of β1 integrins, delta-like 1 (DLL1) and the EGFR antagonist LRIG1. However, there is cell-to-cell variation in the relative abundance of DLL1 and LRIG1 mRNA transcripts. Single-cell global gene expression profiling showed that
Gayan I Balasooriya et al.
Developmental cell, 37(1), 85-97 (2016-04-06)
The steady-state airway epithelium has a low rate of stem cell turnover but can nevertheless mount a rapid proliferative response following injury. This suggests a mechanism to restrain proliferation at steady state. One such mechanism has been identified in skeletal

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service